vTv Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | $-1.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $36.84M | $1.65 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | After market close | – | $-0.58 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | $-0.92 |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements vTv Therapeutics filed with the SEC
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
1Nasdaq: VTVT Committed to Improving the Lives of People with Diabetes March 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
1Nasdaq: VTVT Committed to Improving the Lives of People with Diabetes February 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
Other events · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Improving the Lives of Millions of Patients with Type 1 Diabetes Nasdaq: VTVT
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Improving the Lives of Millions of Patients with Type 1 Diabetes NASDAQ: VTVT
Regulation FD disclosure · EX-99.1 to Form 8-K
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Selected as Executive Vice President and General Counsel of vTv Therapeutics
Other events · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K